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Abstract Cilia are antenna-like organelles found on the
surface of most cells. They transduce molecular signals
and facilitate interactions between cells and their
environment. Ciliary dysfunction has been shown to
underlie a broad range of overlapping, clinically and
genetically heterogeneous phenotypes, collectively
termed ciliopathies. Literally, all organs can be affected.
Frequent cilia-related manifestations are (poly)cystic
kidney disease, retinal degeneration, situs inversus,
cardiac defects, polydactyly, other skeletal abnormalities,
and defects of the central and peripheral nervous
system, occurring either isolated or as part of syn-
dromes. Characterization of ciliopathies and the decisive
role of primary cilia in signal transduction and cell
division provides novel insights into tumorigenesis,
mental retardation, and other common causes of mor-
bidity and mortality, including diabetes mellitus and
obesity. New technologies (“Next generation sequencing/
NGS”) have considerably improved genetic research and
diagnostics by allowing simultaneous investigation of all
disease genes at reduced costs and lower turn-around
times. This is undoubtedly a result of the dynamic
development in the field of human genetics and
deserves increased attention in genetic counselling and
the management of affected families.
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Introduction
Defective cellular organelles such as mitochondria, perox-
isomes, and lysosomes are well-known causes of human
disease. In line with a unifying disease concept, disorders
often derive their name from the respective dysfunctional
organelle, e.g., mitochondriopathies. The cilium, another
cellular structure, currently arises much interest and an
emerging number of diseases with a wide phenotypic
spectrum have been shown to be related to ciliary
dysfunction, now collectively termed “ciliopathies”.
In humans, four different types of cilia that differ in
structure and motility are known (9+0 vs. 9+2 structure,
immotile vs. motile; all combinations are known). All
have in common an axoneme that is composed of nine
microtubule doublets (some with an additional central
pair=9+2 structure and dyneins that power ciliary
motility) derived from a modified centrosome, the basal
body, in quiescent cells. The cilium–centrosome com-
plex has been conserved throughout evolution and
across organ systems [34]. Primary cilia are usually
immotile with a 9+0 structure, as tiny hair-like projections
cilia extend about 5–10 μm from the apical membrane of
polarized cells into the extracellular environment [59] (Fig. 1).
An elaborate, highly conserved process (intraflagellar trans-
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port/IFT) along the microtubule core organizes the transport
of proteins into (anterograde) and out of (retrograde) the
cilium, and this process is needed for formation, mainte-
nance, and function of the cilium [53].
Over the past decade, it has become obvious that cilia
are practically ubiquitously present in all organs which
explain the broad range of phenotypes associated with
defects in their function and/or structure [20]. They
represent versatile tools for various cellular functions
including proliferation, apoptosis, and planar cell polarity
that have been shown to be crucial for proper epithelial
function and normal diameters of tubular structures [25].
Overall, cilia can be best understood as environmental
rheostats and cellular signaling centers that detect and
orchestrate a bunch of different extracellular stimuli
through specific ciliary receptors (e.g., fluid flow, light,
smell, hormones, growth factors, and other chemokines).
Cilia act as mechano-, chemo-, and osmosensors and
mediate multiple pathways (Wnt, Hedgehog, Notch,
JAK-STAT, etc.) essential for normal development, but,
if disrupted, lead to early developmental defects and
cancer. In line, cilia play a crucial role in cell cycle
regulation responsible for the coordination of cancer-
related signaling molecules with opposite effects on
tumorigenesis, either repressing or stimulating depending on
the context [29, 77].
Primary ciliary dyskinesia and Kartagener syndrome
Many people may know motile cilia from the respira-
tory tract and their function to generate flow-clearing
mucus. In contrast to primary cilia with a typically 9+0
structure, these motile counterparts usually additionally
contain a central microtubule pair (9+2 structure) that is
thought to impart additional function. Motile cilia lining
the upper and lower respiratory tract are defective in
patients with primary ciliary dyskinesia (PCD), also
known as immotile cilia syndrome. As a consequence of
impaired mucociliary clearance, recurrent airway infec-
tions and lung damage such as bronchiectases occur [6].
Alterations in the left–right organization of the internal
organ positioning such as situs inversus and situs
ambiguous are observed in 50% of PCD patients (then
called Kartagener's syndrome) and can be explained by
dysfunctional nodal cilia during early embryogenesis.
Less common are other heterotaxy features such as
asplenia/polysplenia and congenital heart defects. Due to
the fact that sperm tail axonemes (flagella) display a
comparable ultrastructure as respiratory cilia, a consider-
able proportion of male PCD patients have reduced
fertility. PCD is not only clinically, but also genetically
heterogeneous (Table 1). In line with ultrastructural
analyses that reveal defective outer dynein arms in most
patients, autosomal recessive mutations have been de-
scribed in genes encoding components of the outer dynein
arms, radial spokes, and cytoplasmic pre-assembly factors
of axonemal dyneins. Detailed characterization by electron
microscopy, immunofluorescence, and high-speed video-
microscopy, usually only available in specialized centers,
is most helpful in making a specific diagnosis.
A clear-cut distinction between motile and immotile cilia
and their microtubule-based inner structure is not as easy as
often thought, and there is increasing evidence for some
overlap which invite additional scrutiny of motile cilia
dysfunction in patients with primary cilia-related disorders
and vice versa. For example, altered structure and function
of motile cilia in airway epithelia have been demonstrated
in patients with Bardet–Biedl syndrome [61]. Likewise, it
Fig. 1 Schematic diagram of a primary cilium and associated
processes. The inner ciliary structure is defined by the axoneme
composed of nine microtubule doublets derived from the basal body
and mother centriole of the centrosome (inset displays cross-section
revealing 9+0 architecture). Along this microtubule core, the transport
of proteins toward the tip of the cilium (anterograde, by kinesin-2 with
its major component KIF3A) and in the retrograde direction towards
the cell body (by dynein-2) is organized by an elaborate process called
intraflagellar transport (IFT). Cilia are small antennae that detect a
variety of different extracellular stimuli and orchestrate multiple
signaling pathways with nuclear trafficking of some molecules
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has been shown that both motile and immotile cilia have
sensory functions.
Polycystic kidney disease and other cystic kidney
disorders
Polycystic kidneys initially paved the way for the mean-
while large group of cilia-related disorders, and it is
becoming increasingly evident that most ciliopathies have
a renal cystogenic component, making kidney cyst forma-
tion a hallmark feature of ciliopathies. The first link
between cilia and cystic kidney disease was given by
Pazour and colleagues in 2000 when they observed
shortened cilia in the kidneys of orpk mice, a model for
polycystic kidney disease bearing mutations in the gene
encoding the intraflagellar transport protein IFT88 [50].
Polycystic kidney diseases (autosomal dominant polycys-
tic kidney disease (ADPKD) and autosomal recessive
polycystic kidney disease (ARPKD)) and other cystic
kidney disorders including the nephronophthisis-
medullary cystic kidney disease complex are clinically
and genetically heterogeneous and may already mani-
fest in utero. Progressive fibrocystic renal changes are
often accompanied by hepatobiliary changes and some-
times other extrarenal abnormalities [19].
For the detection of even small cysts, ultrasound is
usually the first step in the diagnostic process as it is cheap,
readily available, noninvasive, and highly sensitive. In
certain cases, computed tomography (CT) and magnetic
resonance imaging (MRI) may be useful. Compared to
ultrasound, CT and MRI are both known to allow for better
and more accurate detection of smaller cysts, especially
when an intravenous contrast agent is being used.
Autosomal dominant polycystic kidney disease
ADPKD is the most frequent life-threatening genetic
disease with a prevalence of 1/400–1,000, affecting ∼12.5
million individuals worldwide. About 5–10% of adult
patients who require renal replacement therapy are affected
by ADPKD that is transmitted in an autosomal dominant,
fully penetrant fashion. The majority (∼80–85%) carries a
germline mutation in the PKD1 gene on chromosome
16p13, whereas about 15–20% harbor a mutation in the
PKD2 gene on chromosome 4q21 [32]. The encoded
proteins polycystin-1 and polycystin-2 are both glycosy-
lated integral membrane proteins that interact via their C-
terminal coiled-coil domains. Polycystin-2 is a member of
the transient receptor potential protein superfamily and
known to function as a divalent cation channel particularly
involved in cellular Ca2+ signaling [69].
PKD1 sequencing is complicated by the presence of six
pseudogenes in a duplicated region adjacent to the original
PKD1 locus. It is still a matter of debate if these
pseudogenes are merely “junk” or functional DNA. Several
lines of evidence show that some pseudogenes are “alive”
with functional roles in gene expression and regulation,
e.g., by acting as microRNA decoys [51]. Mutation analysis
in ADPKD has much improved during recent years, and it
is now generally possible to detect the disease-causing
mutation in most affected families. Sequencing of the large
and structurally complex PKD1 gene is usually the first
step; if negative, it is followed by PKD2 sequencing and
finally MLPA (multiplex ligation-dependent probe amplifi-
cation) analysis of both genes to detect larger deletions.
Diagnosis of ADPKD by ultrasound is established in at-
risk individuals aged 15 to 39 years if three or more (unilateral
or bilateral) renal cysts are detected. About 60% of children
Table 1 Primary ciliary dyskinesia and Kartagener syndrome
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younger than 5 years of age and 75 to 80% of children aged 5–
18 years with a known PKD1 mutation had renal cysts
detectable by ultrasound. In general, the finding of even one
renal cyst should alert a pediatrician to the possibility of
ADPKD because simple cysts are otherwise extremely rare
in childhood. In children with a 50% risk of ADPKD, the
finding of one cyst can thus be considered diagnostic [52].
Clinical symptoms usually do not arise until adulthood;
however, there is striking phenotypic variability even within
the same family indicating that modifying genes, epigenetic
mechanisms, and/or environmental factors considerably in-
fluence the clinical course in ADPKD. About 2% of ADPKD
patients present with early clinical manifestations before age
15 years. Among these are cases with significant perinatal
morbidity and mortality sometimes indistinguishable from
severe autosomal recessive polycystic kidney disease
(ARPKD). Notably, affected families with early-manifesting
offspring have a high recurrence risk for the birth of a further
child with similar clinical manifestation; an information that
should be shared with afflicted families and that clearly hints
at a common familial modifying background for early and
severe disease expression [70].
Renal cysts can vary considerably in size and appearance
arising from all segments of the nephron (Fig. 2). Usually, they
show progressive enlargement and may become disconnected
from the tubular space. The Consortium for Radiologic
Imaging for the Study of Polycystic Kidney Disease recently
showed that renal enlargement in ADPKD mimicked
exponential growth. Over a 3-year period among more than
200 patients, the renal volume increased by a mean of
63.4 ml (5.3%) per year resulting from the expansion of cysts
in a continuous process associated with the decline of renal
function. While this leads to progressive destruction of the
adjacent renal parenchyma and massive enlargement of the
kidneys, renal function can long be preserved as functioning
nephrons undergo compensatory hypertrophy [27]. Chronic
renal failure presents in about 50% of patients by the age of
60 years [21]. PKD2 is usually significantly milder than
PKD1 with a lower prevalence of arterial hypertension and
urinary tract infections [39]. Patients with PKD1 develop
end-stage renal disease (ESRD) approximately 20 years
earlier than patients with PKD2, with a median age of onset
of ESRD at 54.3 and 74.0 years, respectively [33]. The
greater severity of PKD1 is due to the development of more
cysts at an early age, not to faster cyst growth [30].
While the kidneys are the main organ involved, ADPKD
is clearly a systemic disorder with profound extrarenal
disease burden. Polycystic liver disease is by far the most
common extrarenal manifestation in ADPKD and usually a
benign disease that may cause mechanical compression or
irritation. Notably, polycystic liver disease can also occur
isolated as an autosomal dominant trait with a mutation in
either PRKCSH or SEC63. Liver cysts affect about 75% of
ADPKD patients in their sixties [5] and usually gain in size
and number as they do in the kidney. Women, especially
those who have used hormones and/or have had multiple
pregnancies, are more often and more severely affected
suggesting that estrogen influences hepatic cyst growth [22,
63]. Estrogen is known to stimulate proliferation of
cholangiocytes, and estrogen receptors are expressed in
epithelial cells lining hepatic cysts [3]. Cysts in other
epithelial organs (e.g., seminal vesicles, pancreas, arachnoid
membrane) and diverticulosis are also common [43, 67].
Among cardiovascular co-morbidities, intracerebral aneur-
ysms play a significant role and are present in about 8% of
ADPKD patients. The prevalence is even higher in patients
with a positive family history for intracerebral aneurysms
and/or subarachnoid hemorrhage. Cardiac valve disease,
particularly mitral valve prolapse, can be diagnosed in
approximately 25% of patients with ADPKD [37].
Therapeutic approaches in ADPKD
The pathomechanism of ADPKD is closely related to
defective intracellular calcium homeostasis and cAMP and
Fig. 2 Enlarged kidney from a patient with autosomal dominant
polycystic kidney disease (ADPKD). Multiple cysts, grossly varying
in size, have massively destructed the renal parenchyma
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mTOR signaling with increased rates of proliferation,
apoptosis, and secretion along with remodeling of the
extracellular matrix [9, 64]. Currently, several therapeutic
clinical trials based on new pathophysiological insights are
running. Hopes had been high that mTOR inhibitors would
at least help delay progression of ADPKD; however, two
separate clinical trials using everolimus and sirolimus
recently failed to halt the decline in renal function [60, 74].
Increased expression of vasopressin V2 receptor (V2R),
c-myc, and epidermal growth factor receptor (EGFR) in
cystic kidneys has led to other therapeutic approaches [68].
Vasopressin is the major adenyl cyclase agonist in the
principal cells of renal collecting ducts generating cAMP as
a known promoter of renal cystic enlargement. Thus, V2R
antagonists may have great potential for drug approval in
cystic kidney diseases. Administration of the V2R antago-
nist OPC31260 in the pcy mouse even led to regression of
already established renal cystic pathology with decreased
proliferation, apoptosis, and interstitial fibrosis. Tolvaptan,
another V2R antagonist, has proven its efficacy in different
rodent models orthologous to human ADPKD, ARPKD,
and nephronophthisis and is currently tested in advanced
clinical trials in patients with ADPKD [68]. Besides the
expected and well-tolerated mild to moderate thirst, no
other significant adverse effect has been reported so far.
Almost exclusive expression of the V2R protein in renal
collecting ducts warrants specificity and safety of the drug
but also implicates that extrarenal PKD manifestations will
not be targeted.
Another promising approach might be intervention with
the long-acting somatostatin-analog octreotide. Its thera-
peutic downstream effect is supposed to be based on
inhibition of cAMP-generated chloride secretion by cyst-
lining epithelia. Octreotide therapy was well tolerated in the
majority of patients and found to inhibit renal and liver
enlargement [14, 36, 54]. The drug might also be effective
in other organs that show cystic alterations such as breast
and ovaries [23]. Whether this therapy form proves
beneficial in the long run has to be tested in further trials
of longer duration with a greater number of patients.
“Neoplasia in disguise”
Jared J. Grantham was the first who called ADPKD
“neoplasia in disguise” because the cystogenic process
resembles profiles often observed in tumors [26, 31].
However, renal cell carcinoma or any other tumor only
rarely develop in human PKD despite the frequency of
hyperplastic polyps and microscopic adenomas in which
aneuploid karyotypes with chromosomal extra-copies can
often be determined. This phenomenon in cell growth and
tumorigenesis has recently been explained by the so-called
aneuploidy paradox which means that chromosome gains
cause a proliferative disadvantage and not advantage as one
may have assumed [76]. The integrity of cilia and the
polycystin complex are required for the maintenance of
mitotic spindle orientation and centrosome amplification [1,
7]. Interventions targeted at cell cycle regulation may thus
be another smart drug approach as demonstrated by
beneficial effects of the cyclin-dependent kinase (CDK)
inhibitor roscovitine on cystic kidney disease in two PKD
mouse models [13].
von Hippel–Lindau disease and tuberous sclerosis
The term “neoplasia in disguise” may also hint at some
similarities between ADPKD and hereditary cancer syn-
dromes such as von Hippel–Lindau (VHL) syndrome and
tuberous sclerosis (TSC) (Table 2). VHL is an autosomal
dominant condition caused by inactivating mutations of the
VHL tumor suppressor gene and characterized by the
development of hemangioblastomas in the brain, spinal
cord, and retina often combined with renal clear cell
carcinoma and pheochromocytoma [40]. Patients with
VHL are also at increased risk for epididymal cystadenomas
and cysts in the kidney and pancreas.
Tuberous sclerosis (TSC) is caused by an autosomal
dominant germline mutation in either TSC1 or TSC2 and
can affect a broad range of organs with a birth incidence of
approximately 1:6,000 [15]. About 90% of patients expe-
rience often intractable seizures and approximately every
second patient shows cognitive impairment, autism, or
other behavioral disorders. Renal manifestations are the
leading cause of death in adult patients [62]; cystic kidney
disease occurs in 50%, angiomyolipomas are diagnosed in
even 80% of TSC patients. Many other parts of the body
(e.g., heart and brain) can also be affected by primarily non-
cancerous tumors. A third of all female patients display
pulmonary involvement, specifically lymphangioleiomyo-
matosis. Frequent skin manifestations in TSC are white
spots, facial angiofibromas, and peri-/subungual fibromas.
Both TSC and VHL intersect with the primary cilium
and the mTOR signaling network known to be upregu-
lated in PKD and several tumor types [38]. Activity of
mTOR is down-regulated by polycystin-1 and the TSC1/
TSC2 tumor suppressor complex, finally resulting in G1-
cell cycle arrest and apoptosis. A synergistic role of
polycystin-1 and the TSC2 gene product tuberin had
already been suggested by the more severe and earlier-
onset PKD phenotype in individuals harboring a deletion
encompassing the adjacent TSC2 and PKD1 genes on
chromosome 16p13 than in patients with a PKD1 mutation
alone. A molecular explanation might be the fact that both
proteins interact and tuberin traffics polycystin-1 to the
plasma membrane [64].
Eur J Pediatr (2012) 171:1285–1300 1289
Autosomal recessive polycystic kidney disease
ARPKD, the recessive counterpart of ADPKD, is caused by
mutations in PKHD1, a large gene on chromosome 6p12
that extends over a genomic segment of almost 500 kb. The
longest open reading frame (ORF) comprises 66 exons
encoding polyductin/fibrocystin, a type I single-pass trans-
membrane protein of 4,074 amino acids [48, 75]. Due to
allelic heterogeneity and a high level of missense mutations
and private changes, mutation analysis for PKHD1 is
laborious. Routine diagnostics has been largely alleviated
by setting up an algorithm that allows the detection of 80%
of PKHD1 mutations by screening only one third of the
gene [11]. Patients with two truncating mutations generally
display a severe phenotype with peri- or neonatal death,
whereas patients surviving the neonatal period usually carry
at least one hypomorphic missense mutation. PKHD1 is the
main gene in ARPKD, but there is compelling evidence for
locus heterogeneity why results that are merely based on
linkage need to be handled with some care.
In contrast to ADPKD, ARPKD typically is a pediatric
disease, although the clinical spectrum is much more
variable than generally presumed and moderately affected
adults have been described [2, 12]. Yet, the majority of
cases are severely affected and identified late in pregnancy
or at birth. Affected fetuses display a “Potter” oligohy-
dramnios phenotype with massively enlarged kidneys,
pulmonary hypoplasia, a characteristic facies, and con-
tracted limbs with club feet. Approximately 30–50% of
affected neonates die shortly after birth from respiratory
insufficiency due to pulmonary hypoplasia and thoracic
compression by the excessively enlarged kidneys (Fig. 3).
By ultrasound, children with ARPKD typically exhibit
characteristic bilateral large echogenic kidneys with poor
corticomedullary differentiation. Unlike ADPKD, the cysts
are usually tiny, remain in contact with the urinary system, and
are confined to the distal tubules and collecting ducts. With
advancing clinical course and development of larger renal
cysts accompanied by interstitial fibrosis, the kidney structure
of ARPKD may increasingly resemble that of ADPKD.
Arterial hypertension, often difficult to control despite multi-
drug treatment, usually develops during the first months of life
and affects up to 80% of children with ARPKD. Careful blood
pressure monitoring is essential to prevent sequelae of
hypertension (e.g., cardiac hypertrophy, congestive heart
failure) and deterioration of the renal function [12].
While the early appearance of ARPKD is typically
clearly dominated by renal manifestations and associated
co-morbidities, histologic liver involvement is present in
every ARPKD patient from early embryonic development
on, reflected by the disease term “Polycystic Kidney and
Hepatic Disease 1 (PKHD1)”. These obligatory liver
Table 2 Polycystic kidney and liver disease, von Hippel–Lindau syndrome and tuberous sclerosis
Disease Main features Gene (locus) Corresponding protein
Autosomal recessive polycystic
kidney disease (ARPKD)
In pre-/perinatal cases: Potter's sequence and
respiratory distress, huge hyperechogenic
kidneys with multiple tiny cysts throughout
cortex and medulla, poor corticomedullary
differentiation. Early arterial hypertension.
Ductal plate malformation always present
(leading to portal hypertension). Rarely,




Typical disease onset in adulthood with arterial
hypertension, proteinuria, hematuria, and/or
renal insufficiency (rarely, early childhood
manifestation). Generally enlarged kidneys
with cysts of different size in all parts of
the nephron. Liver cysts, rare in children.





Numerous liver cysts (usually >20), only few
kidney cysts. Symptoms arise from mass
effect/hepatomegaly. Rarely, intracystic






Hemangioblastomas in brain/cerebellum, spinal
cord, retina, often combined with renal clear
cell carcinoma, pheochromocytoma, epididymal




Epilepsy, cognitive impairment, angiomyolipomas,
cystic kidneys, pulmonary lymphangioleiomyomatosis,
skin manifestations (white spots, angiofibromas)
TSC1 (9q34.13) Hamartin
TSC2 (16p13.3) Tuberin
1290 Eur J Pediatr (2012) 171:1285–1300
changes are characterized by defective remodeling of the
ductal plate with congenital hepatic fibrosis and hyperplas-
tic biliary ducts [19, 71], defined as ductal plate malforma-
tion (DPM) which is also a frequent feature in other
ciliopathies, e.g., Bardet–Biedl, Joubert, Meckel and Jeune
syndrome.
Biliary anomalies may develop at any stage of the
physiologic involution-remodeling process, and the timing
or stage of development determines the resulting clinical
and histological phenotype. Typically, cysts that arise from
small interlobular bile ducts are detached from the biliary
tree, while those that stem from malformation of medium-
and large-sized bile ducts usually maintain connected.
While there are overlaps between each subgroup, bile duct
hamartomas, ARPKD, and other ciliopathies are mainly
manifestations of DPM of the small interlobular bile ducts,
whereas medium-sized intrahepatic ducts are generally
afflicted in ADPKD and polycystic liver disease. Caroli's
disease is usually the result of DPM of large intrahepatic
bile ducts, while choledochal cysts are thought to represent
large extrahepatic DPM [18].
Besides the portal tracts, the remaining liver parenchyma
in ARPKD usually develops normally and liver enzymes,
except for cholestasis parameters that might be elevated, are
characteristically not increased. The hepatobiliary compli-
cations may dominate the clinical picture, particularly in
older patients. Ductal plate malformation leads to progres-
sive hepatic fibrosis and consecutive portal hypertension
that causes hypersplenism with pancytopenia and oesopha-
geal varices with upper gastrointestinal bleeding [12, 28].
Primary management of variceal bleeding includes endo-
scopic approaches, such as sclerotherapy or variceal
banding. Occasionally, portosystemic shunting or liver–
kidney transplantation (sequential or combined) has to be
considered. ARPKD patients with liver cysts due to
extensive dilatations of intra- and extrahepatic bile ducts
(Caroli's disease and syndrome) are at increased risk of
recurrent episodes of ascending bacterial cholangitis that
may cause fulminant hepatic failure [41]. Occasionally,
ARPKD patients present with an organ-specific phenotype,
i. e., either an (almost) exclusive renal phenotype or a
predominant or mere liver phenotype. In accordance,
Pkhd1/PKHD1 mutations can cause isolated congenital
hepatic fibrosis or Caroli's syndrome in mice and men [45].
Nephronophthisis and the medullary cystic kidney
disease complex
Nephronophthisis (NPH) comprises a clinically and genet-
ically heterogeneous group of autosomal recessive tubulo-
interstitial cystic kidney disorders that represents the most
frequent genetic cause of end-stage renal disease in children
and young adults and typically initially presents with a
urinary concentrating defect [35, 56]. The most common
form, juvenile NPH, usually starts during the first decade
with polyuria, polydipsia, and anemia. Patients usually do
not show arterial hypertension before onset of renal failure.
Fig. 3 Baby with autosomal
recessive polycystic kidney
disease (ARPKD). a Distended
abdomen due to voluminous
kidneys that lead to respiratory
problems. b Nephrectomized
kidney of this girl. c–d Ultra-
sound showed symmetrically
enlarged echogenic kidneys with
fusiform dilations of collecting
ducts and distal tubules arranged
radially throughout the renal
parenchyma from medulla to
cortex
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On ultrasound, NPH patients generally show normal or
small-sized kidneys with increased echogenicity and also
often loss of cortico-medullary differentiation. Cysts usual-
ly only occur secondarily after patients have progressed to
end-stage renal failure and are typically located at the
cortico-medullary junction. Histologically, tubular basement
membrane thickening and disintegration, tubular atrophy,
and disproportionate tubulo-interstitial fibrosis with mini-
mal inflammation are observed [47].
Medullary cystic kidney disease (MCKD) is often
regarded as the autosomal dominant counterpart of NPH
(NPH–MCKD complex) with a usually later onset of renal
failure than the recessive forms. The ciliary protein
uromodulin (=Tamm–Horsfall glycoprotein), the most
abundant protein in urine of healthy individuals, plays a
major role and is encoded by UMOD on chromosome
16p12 [72]. Mutations in this gene can lead to different
tubulo-interstitial nephropathies including MCKD2, glo-
merulocystic kidney disease, and familial juvenile hyper-
uricemic nephropathy, which may also be caused by
mutations in TCF2 (HNF1ß) and REN (Renin).
To date, 12 genes (NPHP1-12) have been described for
recessive NPH plus XPNPEP3 in which mutations cause an
NPH-like phenotype (NPHP1L) (Table 3). Given that these
genes only account for about the half of all NPH cases,
further heterogeneity can be expected. NPHP1 on chromo-
some 2q13 is the most commonly mutated gene in NPH. In
large series of patients, a homozygous deletion of NPHP1
was present in 20–40% of cases [35, 56]. Heterozygous
deletions were found in another 6% of patients, harboring a
concomitant point mutation on the other parental NPHP1
allele [56]. Other NPHP genes described so far may only
contribute a minor part to the total mutational load of
typical NPH. Mutations in NPHP2/INVS and NPHP3 lead
to infantile and adolescent nephronophthisis, but often do
not impress as typically NPH-like (e.g., cortically located
microcysts) and may mimic polycystic kidney disease with
enlarged kidneys and sometimes even prenatal manifesta-
tion of Potter's sequence.
The characterization of the different NPHP proteins
(nephrocystins) have considerably supported the under-
standing of the cystogenesis process and of cilia-related
disorders in general. As an example, inversin (NPHP2)
has been demonstrated to be crucial in the regulation of
Wnt signaling known to be involved in planar cell
polarity (PCP). If inversin is defective, the canonical
Wnt pathway will dominate over the non-canonical form
with subsequent disruption of apical–basolateral polarity
in renal epithelial cells. Likewise, a bunch of other
signaling pathways as, e.g., hedgehog transduction have been
shown to be altered in NPH and other ciliopathies [65].
As discussed, proper ciliary function at the embryonic
node is responsible for the spatially controlled and
coordinated process that leads to well-defined right- and
Table 3 Nephronophthisis and the medullary cystic kidney disease complex
Disease Main features Gene (locus) Corresponding protein
Nephronophthisis (NPH) and
Senior-Loken syndrome (SLSN)



























Autosomal dominant UMOD (16p12.3) Uromodulin/Tamm-
Horsfall proteinNormal or reduced kidney volumen
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left-sided positions of abdominal and thoracic structures
within the body. Any organ arrangement other than situs
solitus and situs inversus is referred to as situs ambiguous
often associated with various other anomalies (heterotaxy).
For example, patients with Ivemark syndrome and muta-
tions in NPHP3 often show asplenia/polysplenia and
cardiac defects in addition to renal-hepatic-pancreatic
dysplasia [10].
Joubert syndrome and related disorders
Additional clinical features are frequent in patients with
NPH and lead to a variety of other ciliopathies including
Senior–Loken (SLSN) and Joubert syndrome (JS/JBTS)
and related disorders (JSRD) [35]. With the exception of
rare X-linked recessive cases in JBTS10/OFD1, JSRDs
follow autosomal recessive inheritance with 25% recur-
rence risk and constitute a heterogeneous group with
currently 13 causative genes known (Table 4). Clinical
hallmark is the so-called “molar tooth sign” (MTS), a
complex mid-hindbrain malformation with cerebellar ver-
mis hypoplasia visible on MRI (Fig. 4). Clinical correlates
are developmental delay/mental retardation, neonatal irreg-
ular breathing, hypotonia, ataxia, and eye movement
abnormalities [49]. Detection of the MTS should be
followed by a multidisciplinary approach and diagnostic
protocol to assess multiorgan involvement that often
accompanies the neurological features and mainly includes
polydactyly, retinal dystrophy, hepatic fibrosis, NPH, and
other cystic kidney disease phenotypes. In neonates and
young infants, particular attention should be paid to
respiratory and feeding problems. Depending on the extent
and severity of organ involvement, the prognosis varies
considerably among patients with JSRD.
It is well known for ciliopathies that mutations in a
specific gene do not always lead to a specific phenotype.
Clinical severity might depend on the type of mutations
present, such that severe loss-of-function mutations (e.g.,
truncating alleles) lead to severe disease, while more
moderate mutations with residual protein function (e.g.,
hypomorphic missense changes) may give rise to milder
phenotypes with later disease onset and possibly also
slower progression. Overall, genetic, cellular, and biochem-
ical data indicate that most ciliopathies rather represent a
continuum in which the phenotypic outcome is determined
by the nature of the mutation in conjunction with the
genetic background of the respective patient and oligogenic
inheritance patterns. While some genotype–phenotype corre-
lations may allow for prioritization of genes, efficient testing
has been largely alleviated by a new generation of sequencing
technologies (Next-generation sequencing/NGS) and the
possibility of simultaneous investigation of all genes to be
discussed in a patient. This knowledge is particularly useful in
sporadic, single cases from non-consanguineous marriages in
which a direct approach is the only option.
Meckel syndrome
Meckel syndrome (MKS) is allelic to JSRD and related
disorders and resides at the severe end of the broad phenotypic
spectrum of ciliopathies [10]. MKS is an autosomal recessive,
multisystemic disorder of early developmental rather than
degenerative nature, and is considered to be the most frequent
syndromic cause of neural tube defects. Classic disease
manifestations comprise occipital meningoencephalocele,
cystic kidney dysplasia, hepatobiliary ductal plate malforma-
tion, and postaxial polydactyly (Fig. 5). In addition, several
other associated features such as shortening and bowing of
long tubular bones, heart defects, microphthalmia, and cleft
lip/palate have been reported (Table 4). Survival beyond birth
or the neonatal period is unusual with the vast majority of
cases dying in utero.
To date, nine MKS genes have been identified (Table 4)
plus NPHP3 in which mutations cause an MKS-like
phenotype [57]. Currently, it is still hard to give exact
figures on the contribution of each of these genes to the
total mutational load in Meckel syndrome. It is becoming
clear that there is even further genetic heterogeneity in
MKS, while MKS1, MKS3/TMEM67, and MKS6/CC2D2A
might be major MKS genes, followed by MKS4/CEP290.
Mutations in MKS genes are mainly truncating, however,
particularly in MKS3/TMEM67, missense mutations are
also frequent.
Bardet–Biedl syndrome and Alström syndrome
Bardet–Biedl syndrome (BBS) is often called “model
ciliopathy” due to its highly pleiotropic nature with multi-
system involvement [78]. It is characterized by obesity,
hypogonadism, retinal degeneration, polydactyly, mental
retardation, and renal malformations (Fig. 6). Renal disease
is a major cause of morbidity and mortality in BBS and can
be very heterogeneous in phenotype. While some kidneys
impress as NPH with tubulo-interstitial disease, others may
exhibit findings resembling those usually seen in ARPKD
and ADPKD with enlarged, hyperechogenic kidneys and
loss of cortico-medullary differentiation, with or without
macrocysts. The broad phenotypic spectrum also affects
other organs, and a variety of additional features have been
described in patients with BBS, such as hearing loss,
anosmia, defects in thermosensory and nociceptive sensa-
tion, Hirschsprung disease, hepatic changes, metabolic
defects, and diabetes mellitus.
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Table 4 Other syndromic ciliopathies
Disease Main features Gene (locus) Corresponding protein
Bardet–Biedl syndrome (BBS) Obesity, hypogonadism, retinal degeneration,
polydactyly, cognitive impairment, cystic
kidneys of different type, DPM, diabetes
mellitus and other metabolic defects,


















Alstrom syndrome Obesity, retinal dystrophy, sensorineural
hearing loss, dilated cardiomyopathy,
progressive pulmonary, hepatic and





Ivemark syndrome Renal-hepatic-pancreatic dysplasia
with disturbed body symmetry
(situs ambiguous/inversus) and




Joubert syndrome (JBTS) and
related disorders (JSRD)
Complex mid-hindbrain malformation
with cerebellar vermis hypoplasia
(Molar Tooth Sign/MTS). Clinical
correlates are developmental delay/mental
retardation, neonatal irregular breathing,
hypotonia, ataxia, and eye movement
abnormalities. Other frequent features
are polydactyly, retinal dystrophy, DPM,













TCTN2 (12q24.31) Tectonic 2
ATXN10 (22q13.31) Ataxin 10
Meckel syndrome (MKS) Usually, lethal disorder with occipital
meningoencephalocele, cystic kidneys,
DPM, polydactyly, shortening and
bowing of long tubular bones, congenital









TCTN2/MKS8 (12q24.31) Tectonic 2
B9D1 (17p11.2) B9D1
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A total of 16 genes have been identified to date
(Table 4). BBS1 and BBS10 are major genes in BBS and
significantly contribute to the total mutational load.
However, figures of about 20% for each of these genes
often mentioned in this context might be too high. Two
mutations, the M390R allele in BBS1 and the C91LfsX5
allele in BBS10, are especially frequent. While the former
mutation is largely absent from non-European populations,
the latter change can be found more or less worldwide. All
other BBS loci are much rarer than BBS1 and BBS10 and
make up only a minor part of the total mutational load [78].
Alström syndrome overlaps with BBS and typically
displays obesity, retinal dystrophy, sensorineural hearing
loss, and endocrinological features, such as, e.g., hypogo-
nadism, diabetes mellitus, hypothyroidism, and hyperlipid-
emia. Other features that may point to the correct diagnosis
Fig. 4 Axial (a) and sagittal (b)
MRI of a patient with Joubert
syndrome demonstrating the
complex mid-hindbrain malfor-
mation typical for JSRD with
molar tooth sign (MTS) (a) and
cerebellar vermis hypoplasia (b)
Table 4 (continued)
Disease Main features Gene (locus) Corresponding protein
B9D2 (19q13.2) B9D2
Orofaciodigital syndrome 1 (OFD1) X-linked dominant condition with
embryonic male lethality. Malformations
of oral cavity/teeth, face, and digits
frequently associated with CNS
abnormalities and cystic kidney





Severely constricted thoracic cage with
short ribs often leading to respiratory
insufficiency. Further skeletal findings
include polydactyly, short long
bones, trident acetabular roof. Diverse






Ellis-van Creveld syndrome (EVC) Chondroectodermal dysplasia with
disproportionate short stature,
acromesomelic shortening of limbs,
short ribs, postaxial polydactyly,
dysplastic nails and teeth with oral
frenulae, congenital heart defects
EVC (4p16.2) EVC






ectodermal defects (sparse slowly growing






Most ciliopathies are primarily inherited in an autosomal recessive manner (or sometimes in an oligogenic way)
DPM ductal plate malformation, PKD polycystic kidney disease
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are dilated cardiomyopathy and progressive pulmonary,
hepatic, and renal failure. Importantly, most patients have
normal intelligence in contrast to BBS patients who are
often mentally retarded. The only gene known so far for
Alström syndrome is ALMS1 on chromosome 2p13, and
most individuals with a typical phenotype harbor two
clearly pathogenic mutations in this recessive disease gene




In view of the various skeletal phenotypes in ciliopa-
thies, it is not surprising that primary cilia play a crucial
role in skeletal and chondral development. Clinical
overlap between the different short rib-polydactyly
syndromes and other osteochondrodysplasias clearly
support allelism between some of these ciliopathies as
part of a large disease spectrum.
Jeune syndrome, also known as asphyxiating thoracic
dystrophy (ATD), belongs to the heterogeneous group of
short rib-polydactyly syndromes frequently characterized
by perinatal lethality due to short ribs with a narrow, bell-
shaped chest which restricts the growth and expansion of
the lungs and finally leads to respiratory insufficiency
(Table 4). Further hallmarks are inconstant polydactyly,
short long bones, a trident acetabular roof, and diverse
multisystem organ abnormalities of the ciliopathy spectrum
[17]. So far, autosomal recessive mutations have been
identified in four genes; however, further genetic heteroge-
neity is certain given that many patients with a clear
phenotype do not carry mutations in one of these genes.
Three of the known genes encode proteins that are involved
in intraflagellar transport: DYNC2H1 encodes the cytoplas-
mic dynein 2 heavy chain 1, IFT80 is part of the
intraflagellar transport complex B and also known as WD
repeat-containing protein 56 (WDR56), and TTC21B codes
for the retrograde intraflagellar transport protein IFT139
with several tetratricopeptide (TPR) domains [16]. In
addition, mutations have been described in the gene
encoding the NIMA-related kinase NEK1 with a proposed
function in cell-cycle regulation and ciliogenesis [66].
Considerable overlap with ATD shows the chondroectoder-
mal dysplasia Ellis-van Creveld (EVC) syndrome which is
Fig. 5 Fetus with Meckel syndrome. a Phenotype with occipital
meningoencephalocele and a massively malformed brain resembling
anencephaly. b Postaxial hexadactyly. c Bilateral considerably en-
larged kidneys interspersed with small, pinhead-sized cysts. d Cystic
kidney with considerable interstitial fibrosis. e Ductal plate malfor-
mation characterized by dysgenesis of the hepatic portal triad with
hyperplastic biliary ducts and congenital hepatic fibrosis
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characterized by disproportionate short stature with acromeso-
melic shortening of limbs, short ribs, postaxial polydactyly,
and dysplastic ectoderm-derived structures such as nails and
teeth with oral frenulae [8]. About two thirds of all patients
have a congenital heart defect, specifically abnormalities of
atrial and atrioventricular septation. Autosomal recessive loss-
of-function mutations in EVC and EVC2, located in a head-
to-head configuration on chromosome 4p16, have been
identified as causative in individuals affected with EVC.
Both EVC genes have been shown to encode positive
mediators of Hedgehog signal transduction and localize to
the basal bodies of primary cilia. Allelic to EVC is the milder
autosomal dominantly inherited phenotype Weyers acrodental
dysostosis. Those patients usually carry a mutation in the last
coding exon of EVC2 that lead to production of a truncated
protein with potential gain-of-function characteristics [55].
The phenotype of individuals with ATD and EVC may
overlap with that of patients with cranioectodermal dyspla-
sia (CED, Sensenbrenner syndrome) characterized by
dolichocephaly, rhizomelic dwarfism, ectodermal defects
(sparse slowly growing hair, dental and nail hypo-/dyspla-
sia), and tubulo-interstitial nephropathy which may lead to
end-stage renal failure [42]. Mutations have been recently
described for CED in three genes that all encode compo-
nents of the intraflagellar transport (IFT43, IFT121, and
IFT122) and are known to play a crucial role in the assembly
and maintenance of primary cilia [24, 73] (Table 4).
Concluding remarks and rational genetic testing
approaches
We have learned that there is huge clinical variability in
cilia-related disorders even within the same family. How is
it possible that one sibling is profoundly affected, whereas
another one shows only mild clinical features? Classical
Mendelian inheritance patterns with single-locus allelism
are insufficient to explain phenomena as variable expres-
sivity and incomplete penetrance. It is rather likely that
stochastic, epigenetic, and environmental factors modify the
phenotype. Furthermore, oligogenic inheritance with varia-
tions across multiple sites influences the clinical outcome and
Fig. 6 Two brothers affected
with Bardet–Biedl syndrome
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is consistent with a “mutational load theory” [4]. Such
“additional” alleles, so-called second-site modifiers, may
exert an aggravating effect in an epistatic way and contribute
to early and severe disease expression.
Next-generation sequencing (NGS) provides rapidly
growing insight in these challenging issues and has
significantly improved genetic diagnostics. Conventional
(Sanger) sequencing facilities are expensive with very
limited capacities and thus only allow for a stepwise
approach dependent on mutation frequencies and the ethnic
origin and phenotype of the patient. In case of parental
consanguinity and in multiplex pedigrees with more than
one affected child, linkage analysis with subsequent gene
sequencing in case of compatible haplotypes might be an
option. However, in the end, all of these conventional
approaches are usually more cost- and time-intensive than a
primary NGS-based approach that allows for massively
parallel sequencing of all disease genes which may have to
be discussed in patients of the ciliopathy spectrum. Given
overlapping disease phenotypes and extensive allelism, it is
more the rule than the exception that multiple, often dozens
of genes, have to be considered to be disease-relevant in
one of these patients.
The elucidation of molecular mechanisms that explain some
of the phenotypic variability has important implications for the
understanding of cilia-related disorders. It can be hypothesized
that the altered dosage of disease proteins severely disturbs
converging pathways, network integrity, and finally cell
homeostasis [46, 58]. It is to be expected that similar findings
describe a general disease concept not confined to ciliopathies
and also apply for unexplained variable disease expression in
other conditions called monogenic so far. Those aspects
deserve increased attention in genetic counselling and the
management of affected families.
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